IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)

Authors:

Abstract
Background: The global Phase III IMpower132 study evaluated the addition of atezo to platinum-based pem combinations as 1L treatment (tx) for patients (pts) with metastatic non-squamous NSCLC tumours lacking sensitizing EGFR or ALK mutations. IMpower132 met its co-primary endpoint of PFS in the ITT population and showed numerical improvements in OS. We performed exploratory efficacy analyses to assess clinical benefit in key subgroups.